Home
overview

For the latest COVID-19 Travel restrictions and recommendations please click here

SMi’s 5th Annual Conference
3D Cell Culture
February 09-10, 2022 | Conference
-------------------------------------------------------------------------
3D Cell Culture has gained increasing momentum in the pharmaceutical industry over recent years, with the global 3D Cell Culture market predicted to reach a value of $3.2 Billion by 2027, researchers globally are realising the growing potential of in vitro applications for drug discovery, predictivity and validation, safety and toxicity. 3D Cell Culture technology promises to offer increased translatability in models and reduce the costly rates of drug attrition in the discovery process -- heralding the next major advance in the discovery of pharmaceuticals.

Rising demand for tissue engineering for the treatment of chronic diseases is another key driver of this research -- new technologies in the form of organ-on-chip, microphysiological systems and 3D bioprinting are all burgeoning areas of the field.

Join us in February 2022, as SMi’s 5th annual 3D Cell Culture Conference brings together industry experts from big pharma, regulatory bodies, and biotech companies to discuss the challenges and drivers of these medical technologies, through case studies of the latest innovations in 3D Cell Culture models, real world examples of applications of new technologies, and insights into 3D bioinks and high throughput screening to give a comprehensive look into this fast growing industry.
yalsadoon@smi-online.co.uk

  • DISCUSS the uses of advanced cell technologies to construct in vitro models of human tissues
  • EXPLORE the regulatory sciences surrounding Microphysiological systems, and their development and adoption for drug safety assessment
  • UNCOVER the major benefits of 3D modelling in enhancing clinical translation and predictability
  • UTILISE 3D cell culture for High Throughput drug discovery and Content screening over traditional 2D methods
  • DELVE into advanced case studies looking into organ models: from organotypic lungs to liver spheroids 

 

Key Job Titles include Head of, Director, Manager of...

  • Complex in vitro models
  • Cell and molecular science
  • Disease models
  • Cell technology
  • Microphysiological systems
  • Microfluidics
  • Toxicology
  • Stem Cell Sciences
  • Tissue Engineering
  • High throughput screening
  • 3D Imaging

     

University College London, GSK; Aixtron Ltd; AstraZeneca; BioLamina AB; Boehringer Ingelheim RCV GmbH & Co KG; Cellbox Solutions GmbH; Cellink; CN Bio Innovations Limited; DMPK; Durham University; Engitix Ltd; Enplas; EPO; European Patent Office; FabRx Ltd; Gadeta B.V.; Genentech; GlaxoSmithKline; GSK; Hitachi High-Technologies Corporation; Institute Pasteur; Lund University; Manchester BIOGEL; Medicines Discovery Catapult; Merck; Merck Healthcare KGaA; Merck KGaA; MHRA; Mimetas; MRC Harwell Institute; MRS Mammalian Genetics; NC3Rs; Newcastle University; Novartis Pharma AG; Novo Nordisk A/S; OpenCell ; Promega UK Ltd; Rousselot - gelatin; Sanofi Pasteur; Sartorius; TreeFrog Therapeutics; Unilever Research Laboratory; University College London; University Of Strathclyde; Viscofan S.A;
 

Conference programme

8:00 Registration & Coffee

9:00 Chair's Opening Remarks

Stefan Przyborski

Stefan Przyborski, Professor, Durham University
View Bio

9:10 Innovative Advanced Cell Technologies to Bioengineer Human Tissues In Vitro for Use in R&D and Modelling Human Disease

Stefan Przyborski

Stefan Przyborski, Professor, Durham University
View Bio

  • Development of new cell culture devices and platforms to enhance cell growth in vitro
  • Generating highly specialized models of human tissues – examples of skin and intestinal mucosa
  • Modelling human disease – example, novel intestinal inflammatory tissue model of IBD
  • New innovations and developments to further enhance bioengineered tissue technology
  • 9:50 A model for assessing repeated-dose drug toxicity

    Stephen J. Fey

    Stephen J. Fey, Founder and Chief Research Officer, Celvivo
    View Bio

  • Response to- and recovery from- treatment
  • Metabolic reprogramming
  • Clinostat cultures for keeping cells in a dynamic equilibrium

     

  • 10:30 Morning Coffee

    11:00 HTS considerations for implementing complex co-culture models as secondary screening tools

    BanuPriya Sridharan

    BanuPriya Sridharan, Investigator, GSK
    View Bio

  • Traditional HTS utilizes tumor cells in two-dimensional format that fail to recapitulate the complex tumor microenvironment (TME) morphology and do not translate well to in vivo and clinical outcomes
  • We developed a versatile triculture model of NSCLC that incorporates cancer associated cells such as normal lung fibroblasts and normal bronchiolar epithelial cells, and, components of the extracellular matrix (ECM), in the context of developing robust, scalable and functional assays
  • To assess cytotoxicity, tumor cell viability was determined via cell Titer-Glo or inherent GFP expression in the tumor cells by high content analysis (HCA)
  • This allowed the screening of PARP inhibitors across drug sensitive and resistant cell lines in traditional versus triculture platforms
     
  • 11:40 3D Bioprinted Human Skeletal Muscle Models for In Vitro Physiological Drug Screening

    Hansjoerg Keller

    Hansjoerg Keller, Senior Principal Scientist, Novartis Institutes for BioMedical Research

  • In vitro human microphysiological assays boost drug development
  • 3D bioprinting enables the fabrication of complex human tissue in vitro models for drug discovery
  • 3D bioprinted human skeletal muscle models mimic pharmacological regulation of muscle contractile force
  • 3D bioprinted contractile human skeletal muscle models allow functional screening of test compounds
     
  • 12:20 Networking Lunch

    13:20 Advancing Regulatory Science Through Innovation -- In Vitro Microphysiological Systems

    Suzanne Fitzpatrick

    Suzanne Fitzpatrick, Senio Advisor for Toxicology, FDA
    View Bio

    • Regulation keeping pace with advances in basic and applied science and technology
    • Identifying modern toxicological tools that will improve preclinical safety predictions for regulatory use
    • Developing in vitro Microphysiological systems to bring innovative new technologies into the regulatory paradigm
    • Collaborating to develop organs-on-a-chip to screen for safe and effective products with more efficiency than current methods
     

    14:00 Human tissue-specific extracellular matrix 3D models: a unique approach for novel target identification and drug screening

    Luca Frenguelli

    Luca Frenguelli, Senior Scientist, Engitix Therapeutics

  • Development of decellularized tissue-specific extracellular matrix (ECM) scaffolds
  • Advantages of using ECM-based 3D models compared to two-dimensional models on plastic
  • Use of tissue-specific ECM hydrogels as a scalable and reproducible model to mimicking human disease, an overview
  • 14:40 Implementation of Organoids and Microphysiological systems for pre-clinical drug discovery

    Jason Ekert

    Jason Ekert, Senior Director and Head of Complex In Vitro Models, GlaxoSmithKline
    View Bio

  • Development of an Organoid workflow and platform
  • Latest progress in qualifying and implementing disease relevant and safety models using organoids and microphysiological systems
  • Highlight the activities of consortia to help drive standardization of MPS
     
  • 15:20 Afternoon Tea

    15:50 HUB Organoids™: a revolutionary patient-derived in vitro model for drug screening and patient stratification

    Robert Vries

    Robert Vries, CEO, Hubrecht Organoid Technology
    View Bio

  • The discovery of adult stem cells allowed the development of patient-derived HUB Organoids
  • HUB Organoids revolutionize 3D cultures by bringing patients in the lab and improving translatability and predictivity
  • HUB Organoids are a robust, scalable, and reproducible system for drug screening
  • The future of personalize medicine: HUB Organoids as a diagnostic tool
  • 16:30 Assessing the applicability of 3D human liver spheroids in early safety screening

    Freddy Van Goethem

    Freddy Van Goethem, Scientific Director, Fellow, Janssen (Johnson & Johnson)
    View Bio

  • The use of 3D liver spheroids to predict drug-induced liver injury, an introduction.
  • Exploring the applicability of transcriptomic profiling.
  • Proof of concept study
     
  • 17:10 Chair’s Closing Remarks and Close of Day One

    Stefan Przyborski

    Stefan Przyborski, Professor, Durham University
    View Bio

    8:30 Registration & Coffee

    9:00 Chair's Opening Remarks

    Philip Hewitt

    Philip Hewitt, Global head of early Investigative Toxicology, Merck Healthcare KGaA
    View Bio

    9:10 Application/Characterization of Organ-on-a-Chip Platforms from Preclinical Species in Drug Safety and ADME Testing

    Terry Van Vleet

    Terry Van Vleet, Director of Investigative Toxicology, AbbVie
    View Bio

  • The need and applications for animal cell-based chips in safety assessment of drugs
  • Challenges and barriers to building chips from animal cells
  • An approach to building animal cell chips, the outcome of that effort, and lessons learned
  • Need for improved value compared to spheroids for increased cost/time
  • 9:50 Micro-physiological systems (MPS): Where are we now?

    Pedro Pinto

    Pedro Pinto, Laboratory Lead, University of Greifswald – Medical Centre
    View Bio

  • MPS in research and development
  • Advantage of MPS models
  • Practical applications of MPS
     
  • 10:30 Morning Coffee

    11:00 Advanced intestinal models for preclinical safety: validation of an organ-on-a-chip system for early screening

    Philip Hewitt

    Philip Hewitt, Global head of early Investigative Toxicology, Merck Healthcare KGaA
    View Bio

  • Comparison of 2D, 3D and OOAC cell models: which context of use is each is fit for
  • Assessment of iPSC derived colon organoids
  • Pre-validation and implementation of OOAC small intestine model (CaCo2)
  • Future perspectives and more complex intestinal models?
     
  • 11:40 Development and adoption of 3D and microphysiological systems for drug safety assessment

    Caroline Archer

    Caroline Archer, Associate Principal Scientist, AstraZeneca

  • Outline the context of use of microphysiological systems (MPS) to generate safety and efficacy data for drug development with improved clinical relevance over more traditional 2D cell culture and animal models
  • Highlight examples of data generated from these systems that demonstrate the utility of MPS for safety assessment
  • Current challenges to the adoption and/or development of MPS in the pharmaceutical industry

     

  • 12:20 Networking Lunch

    13:20 Complex in vitro models: a scientific and 3Rs perspective

    Catherine Vickers

    Catherine Vickers, Head of Innovation, NC3Rs

    Overview of resources provided by the NC3Rs to support the development and adoption of complex in vitro models
    Case studies from our portfolio
    Perspectives on 3Rs benefits now and in the future
     

    14:00 3D uHTS Models for Chemo Response Profiling of Cancer

    Louis Scampavia

    Louis Scampavia, Scientific Director, Sr, Scripps Research
    View Bio

  • 3D Pancreas and Brain Cancer Modelling
  • 3D Technology and HTS Protocol
  • Primary cell isolation from patients
  • Screening the NCI Oncology Drug Set
  • Dose Response results
  • Drug Gene Network Analysis
  • Synergy studies
     
  • 14:40 Afternoon Tea

    15:10 An immunological tumour infiltration platform for target discovery

    Julian Bahr

    Julian Bahr, Senior Scientist, AstraZeneca
    View Bio

  • Developing a novel three-dimensional spheroid-splenocyte co-culture system
  • Recapitulating in vivo immune infiltration phenotypes by four-color imaging of the co-culture
  • Efficient CRISPR-mediated gene KO in the co-culture system
  • Evaluation of a CRISPR KO screen for immunological tumour infiltration targets using high content imaging
  • 15:50 Growing human bone in a bone-on-chip

    Elisa Budyn

    Elisa Budyn, Mechanical Engineering, Ecole Normale Supérieure Paris-Saclay
    View Bio

  • New bone formation by human mesenchymal stem cells (MSCs) in vitro is a challenge. A bone-on-chip based on human decellularised native bone is proposed as a physiologically relevant 3D environment for human bone cell recellularization
  • The bone-on-chip successfully led to stem cell derived osteocytes (SCDOs) from either primary adult MSCs or foetal osteoblast progenitors. FTIR and histo-chemistry showed the cells produced a mineralised collagen matrix mimicking the chemical heterogeneity of native bone. Confocal microscopy showed the matrix’ layered microstructure
  • Fluorescent microscopy showed the cells adapted their calcium response to the expected in vivo mechanical stimulations at different stages of differentiation. The new bone displayed a flexural modulus ranging from 25 to 100% of the decellularised bone stiffness between 109 and 126 days
  • The bone-on-chip offers promising opportunities for organ culture up to over 26 months for bone formation study, cell diagnosis or cell reprogramming
     
  • 17:10 Chair’s Closing Remarks and Close of Day Two

    Philip Hewitt

    Philip Hewitt, Global head of early Investigative Toxicology, Merck Healthcare KGaA
    View Bio

    +

    FEATURED SPEAKERS

    BanuPriya Sridharan

    BanuPriya Sridharan

    Investigator, GSK
    Caroline Archer

    Caroline Archer

    Associate Principal Scientist, AstraZeneca
    Catherine Vickers

    Catherine Vickers

    Head of Innovation, NC3Rs
    Elisa Budyn

    Elisa Budyn

    Mechanical Engineering, Ecole Normale Supérieure Paris-Saclay
    Freddy Van Goethem

    Freddy Van Goethem

    Scientific Director, Fellow, Janssen (Johnson & Johnson)
    Hansjoerg Keller

    Hansjoerg Keller

    Senior Principal Scientist, Novartis Institutes for BioMedical Research
    Jason Ekert

    Jason Ekert

    Senior Director and Head of Complex In Vitro Models, GlaxoSmithKline
    Julian Bahr

    Julian Bahr

    Senior Scientist, AstraZeneca
    Louis Scampavia

    Louis Scampavia

    Scientific Director, Sr, Scripps Research
    Luca Frenguelli

    Luca Frenguelli

    Senior Scientist, Engitix Therapeutics
    Pedro Pinto

    Pedro Pinto

    Laboratory Lead, University of Greifswald – Medical Centre
    Philip Hewitt

    Philip Hewitt

    Global head of early Investigative Toxicology, Merck Healthcare KGaA
    Robert Vries

    Robert Vries

    CEO, Hubrecht Organoid Technology
    Stefan Przyborski

    Stefan Przyborski

    Professor, Durham University
    Stephen J. Fey

    Stephen J. Fey

    Founder and Chief Research Officer, Celvivo
    Suzanne Fitzpatrick

    Suzanne Fitzpatrick

    Senio Advisor for Toxicology, FDA
    Terry Van Vleet

    Terry Van Vleet

    Director of Investigative Toxicology, AbbVie

    Anne Rios

    Principal Investigator/ Head of the PMC imaging center, The Princess Maxima Center of Pediatric Oncology
    Anne Rios

    Anne Rios

    Principal Investigator/ Head of the PMC imaging center, The Princess Maxima Center of Pediatric Oncology
    Anne Rios

    BanuPriya Sridharan

    Investigator, GSK
    BanuPriya Sridharan

    BanuPriya was trained as a tissue engineer and worked with Biomaterials and stem cell spheroids for her PhD. After a brief stint at Medimmune she was trained in high throughput screening at the Scripps Research Institute in Florida where she worked with scaling iPSC-derived neurons and pancreatic organoids for HTS. Currently as an investigator at GSK, she works with different research units for -developing context-specific complex in vitro models. Specifically, she works with high throughput scalable platform for combinatorial drug screening in non-small cell lung cancer models and NASH disease modeling using liver-on-a-chip platforms.

     

    Caroline Archer

    Associate Principal Scientist, AstraZeneca
    Caroline Archer

    Catherine Vickers

    Head of Innovation, NC3Rs
    Catherine Vickers

    Elisa Budyn

    Mechanical Engineering, Ecole Normale Supérieure Paris-Saclay
    Elisa Budyn

    Biography: Dr. Elisa Budyn is Professor of Mechanical Engineering at Ecole Normale Superieure de Paris-Saclay. She earnerd an Engineering diploma from E.S.T.P. in France and graduated her M.Sc. and Ph.D. from Northwestern University in 1999 and 2004. Dr. Budyn worked at CNRS LMSSMat Laboratory at Ecole Centrale Paris for one year, after which she joined the University of Illinois at Chicago Mechanical Engineering Department in 2005 as Assistant Professor and joined Ecole Normale Supérieure Paris-Saclay in 2013 as Professor. Her research focuses on bioengineering and mechanobiology of human tissues thanks to the design and implementation of organ-on-chip that enable 3D culture mechanical testing and concurrent computational modeling of cells and tissues such as bone, heart, skin, ligament or liver. She investigates human cell mechanotransduction in in vitro recellularized native tissues in conditions closely mimicking in vivo conditions as test beds for potential patient screening or cells treatments. Her research has been funded by NSF, AFOSR, CNRS, ANR-RHU, Synchrotron SOLEIL and the Farman Institute.

     

    Freddy Van Goethem

    Scientific Director, Fellow, Janssen (Johnson & Johnson)
    Freddy Van Goethem

    Freddy obtained his Ph.D. degree in Science at the Free University of Brussels (Belgium) in 1995. After his post-doc, he joined Janssen (Belgium) as a Study Director for In Vitro Genetic and Predictive toxicology. From 2003 to 2009, Freddy was the chairman of the Belgian Environmental Mutagen Society.
    During his career, he was responsible for the identification and validation of new in vitro test systems to assess the safety profile of compounds in early drug development. Today, he’s heading the Cell Health Assessment group responsible for high throughput liability screening and the evaluation of advanced in vitro models.
     

    Hansjoerg Keller

    Senior Principal Scientist, Novartis Institutes for BioMedical Research
    Hansjoerg Keller

    Jason Ekert

    Senior Director and Head of Complex In Vitro Models, GlaxoSmithKline
    Jason Ekert

    Dr. Jason Ekert is Senior Director, GSK Fellow and Head of the Complex In Vitro Models (CIVM) group at GlaxoSmithKline. He is responsible for an integrated enterprise strategy for R&D applications of complex human-relevant and translatable complex in vitro models (eg Organoids, Microphysiological systems and bioprinting). Before joining GSK he worked at Janssen in biotherapeutic drug discovery. Jason received his PhD from Adelaide University. Post-doctoral training was performed at University of California, Davis and Coriell Institute for Medical Research. He’s currently the chair for the IQ-MPS affiliate. He is a member of the Society for Lab Automation and Screening (SLAS) and Society of Toxicology (SOT).

    Julian Bahr

    Senior Scientist, AstraZeneca
    Julian Bahr

    Julian Bahr has been a Postdoctoral Fellow at AstraZeneca since 2018, where he is developing new 3D models for immunotherapy target discovery. His scientific training began at the National Institutes of Health under Dr. Susan Bates studying the mechanisms of HDAC and MAPK pathway inhibitors on KRAS mutant cancers. He went on to research macrophage-mediated basement membrane remodeling with Dr. Stephen Weiss for his Ph. D. work at the University of Michigan. Julian is passionate about elevating Ph.D. and Postdoctoral science and has continuously held leadership positions in the research organizations he has been a part of.

    Louis Scampavia

    Scientific Director, Sr, Scripps Research
    Louis Scampavia

    Dr. Louis Scampavia is a faculty member at Scripps Research within the Department of Molecular Medicine and a senior scientific director of High Throughput Screening (HTS). The Scripps Molecular uHTS Center is focused on drug discovery to support academic investigators and industrial partners, and its directors Drs. Louis Scampavia and Timothy Spicer leverage over four decades of biomedical research experience. Aside from performing large library uHTS screens, the directors also pursue technology development including the use of 3D cancer screening in high density 1536w plate format for precision medicine drug repurposing testing as well as uHTS drug discovery efforts.

     

    Luca Frenguelli

    Senior Scientist, Engitix Therapeutics
    Luca Frenguelli

    Pedro Pinto

    Laboratory Lead, University of Greifswald – Medical Centre
    Pedro Pinto

    Pedro Pinto is currently leading the research lab affiliated with the Urology clinic of the University Hospital – Greifswald. He previously developed work on the applications the microphysiological systems, with AstraZeneca after his doctoral studies in Pharmaceutical Sciences at Utrecht University. His expertise is centered around renal in vitro models for either drug testing and disease modelling and since 2021 his research group is focusing on the study of kidney and prostate cancer pathophysiology with the use of microphysiological systems.

    Philip Hewitt

    Global head of early Investigative Toxicology, Merck Healthcare KGaA
    Philip Hewitt

    I originally trained as a Medical Biochemist at the University of Birmingham (1986-1989). I worked as a Research Assistant in the Pharmacology and Toxicology Department at Imperial College, London where I received my PhD in the lab of Dr Sharon Hotchkiss. The main theme of the research project was “percutaneous absorption: metabolic and kinetic parameters”. In 1996, I transferred to The University of California, San Francisco, in the Dermatology Department; I spent 18 months there under the guidance of Prof. Howard Maibach. In 1998 I started a permanent position in the Institute of Toxicology at Merck KGaA in Germany, where I established the Molecular Toxicology Group. I am currently responsible for early cytotoxicity screening, hepatotoxicity methods, biomarker monitoring, CYP induction studies, genotoxicity testing and cytokine screening. Alongside the routine screening, and mechanistic assays, I am leading the Merck assessment of more advanced cell models for safety testing and potential animal replacement. I work with several PhD students, on external collaborative projects and I am team representative on several internal pharmaceutical projects.

    Robert Vries

    CEO, Hubrecht Organoid Technology
    Robert Vries

    Robert received his PhD in Biochemistry from the Leiden University Medical Center on a molecular study of oncogenic transformation. He subsequently moved to Stanford University (USA) to do his Post Doc studying neural stem cells. Upon his return to the Netherlands he continued the study of adult stem cells in the group of Prof Hans Clevers at the Hubrecht Institute in The Netherlands.
    In the group of Hans Clevers he was part of the team that developed the breakthrough technology that allowed the expansion of adult stem cells. The so-called Organoid Technology became the basis of the non-profit company ‘Hubrecht Organoid Technology’ (HUB) of which he is currently the CEO.
     

    Stefan Przyborski

    Professor, Durham University
    Stefan Przyborski

    Stefan has over 25 years experience in cell biology with specific interests in cell culture technology and bioengineering human tissues for in vitro applications. He has developed a multi-disciplinary approach to the bioengineering of tissue equivalents through creating bespoke devices and new cell culture platforms. Stefan holds an academic position as Professor in Cell Technology at Durham University. He is also a founder and the Chief Scientific Officer of Reprocell Europe, Glasgow, a biotechnology company that acquired cell technology he developed at Durham University UK. Stefan’s research continues to develop new innovative approaches to manage the growth and function of cultured cells in ways that more accurately reflect native tissues. These human tissue models have multiple applications and will be particularly relevant to modelling human disease, and advance basic research, safety screening and drug discovery.

    Stephen J. Fey

    Founder and Chief Research Officer, Celvivo
    Stephen J. Fey

    Stephen J. Fey

    Founder and Chief Research Officer, Celvivo
    Stephen J. Fey

    Stephen J. Fey has a background in biomedical science having worked in research universities and companies for the past 30 years. He qualified for his PhD at Kings College, London University. He became a pioneer in 2D gel electrophoresis field and used this tool to study cervical cancer, diabetes and cardiovascular problems. He co-founded the Centre for Proteome Analysis at the University of Southern Denmark in 1997 (the world’s first purpose-built proteomics institute) and became CEO when the institute was spun out of SDU in 2006. Subsequently, he co-founded CelVivo in 2014, another spin out company, developing and commercialising 3D cell and tissue culture systems which mimic in vivo physiology and toxicology. He has 125 publications and has filed 37 patents.

    Suzanne Fitzpatrick

    Senio Advisor for Toxicology, FDA
    Suzanne Fitzpatrick


    Dr. Suzanne Fitzpatrick is the Senior Advisor for Toxicology at the US Food and Drug Administration. She is a board-certified toxicologist in the US and in Europe Dr. Fitzpatrick chairs the FDA’s Alternative Methods Work Group that is currently focusing on in vitro Microphysiological Systems. Dr. Fitzpatrick helped develop the FDA DARPA NCATS program on Organs on a Chip and continues to work and give presentations on this evolving area. Dr. Fitzpatrick is an Adjunct Professor at Johns Hopkins University. She received her BA from the University of California at San Diego and her PhD from Georgetown University.
     



     

    Terry Van Vleet

    Director of Investigative Toxicology, AbbVie
    Terry Van Vleet

    Dr. Van Vleet is currently the Director of Investigative Toxicology at AbbVie where he is responsible for Molecular and Computational Toxicology as well as In Vitro Platform Characterization for Preclinical Safety. He also serves as the discovery or development safety project representative on various drug development teams over diverse therapeutic areas. Prior to joining AbbVie, he worked at Bristol-Myers Squibb in positions of increasing responsibility including serving as the Head of Molecular and In Vitro Toxicology group. Dr. Van Vleet received his BS in Zoology (Chem minor) from Weber State University where he graduated summa cum laude. He received his PhD in Toxicology/Molecular Biology from Utah State University (graduating magna cum laude) where he studied the metabolism of procarcinogens by human airway cells. He later completed a Post-Doctoral Fellowship at the Medical University of South Carolina studying mechanism of renal toxicity with a focus on mitochondrial toxicity. Terry is a member of the Society of Toxicology (SOT), American College of Toxicology, and Royal Society of Biology and has published over 40 peer reviewed scientific manuscripts. He is also a Diplomate of the American Board of Toxicology, and a Fellow of the Academy of Toxicological Sciences. He is currently serving as the Past Chair of the IQ MPS Affiliate.

    Sponsors

    VENUE

    Venue To Be Confirmed

    London, United Kingdom

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    Sponsors


    CelVivo

    Sponsors
    https://celvivo.com/

    CelVivo provide a 3D Cell Culture technology mimicking in vivo performance.

    The CelVivo system creates an environment which promotes the growth and maintenance of large 3D tissue mimetic structures, whether they are spheroids, organoids, acini and other aggregates.

    Our ambition is to provide cells with conditions which allow them to develop functionality which closely mimics that seen in the intact organism. To achieve this, we have developed a system which obviates the need for scaffolds, gels or any type of additives which might perturb gene expression away from its natural baseline equilibrium. Furthermore, we have very significantly reduced contact with plastics and reduced shear forces.


    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Venue To Be Confirmed

    London
    United Kingdom

    Venue To Be Confirmed

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SMi.
    Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out